REFERENCES
CPMP / BWP / 268 / 95(Revised): Note for Guidance on Viral Validation Studies: The Design, Contribution, and Interpretation of Studies Validating the Inactivation and Removal of Viruses.
CPMP / BWP / 269 / 95 (Revised) / 2: Note for Guidance on Plasma-Derived Medicinal Products.
DHHS, FDA Docket No. 96D-0058, Federal Register, 61(92), 21882-21981 (1996), Draft Guidance on Viral Safety Evaluation of Biotechnology Products Derived from Cells Lines of Human and Animal Origin (Intern. Conf. on Harmonization, Washington, USA).
Guidelines on the Establishment of Viral Safety for Plasma Fractionation Products, Ministry of Health and Welfare of Japan, Tokyo (1996).
WHO Guidance Document on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Blood Plasma Products, WHO HQ, Geneva (2001).
C. K. Kasper and M. C. Silva, World Federation of Hemophilia. Registry of Clotting Factor Concentrates, Update of January 2003, Los Angeles, USA, CA (2003).
N. Barrett, T. Zeller, H. Riess, et al., Transfusion, 37, 215-220 (1997).
F. Dorner and N. Barrett, Hamostaseologie, 16, 282-285 (1996).
A. Lazo, M. Caple, C. Moore, et al., Vox Sang., 83(4), 313-317 (2002) Broad-spectrum Virus Reduction in Red Cell Concentrates Using INACTINE PEN 110 Chemistry.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Panov, V.P. Principles of Viral Safety of Blood Products (A Review). Pharmaceutical Chemistry Journal 38, 157–165 (2004). https://doi.org/10.1023/B:PHAC.0000034307.71116.57
Issue Date:
DOI: https://doi.org/10.1023/B:PHAC.0000034307.71116.57